Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Yimitasvir Phosphate in Hepatic Impairment
NCT04552808Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of yimitasvir in hepatitis C (HCV) (4 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse Events, Maximum Plasma Concentration (Cmax) and 1 more. Started Oct 2020; status: completed.
02
Drugs
yimitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04552808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552808.